XML 20 R9.htm IDEA: XBRL DOCUMENT
v3.23.1

BALANCE SHEET COMPONENTS | 3 Months Ended
--- | ---
Mar. 31, 2023
Balance Sheet Components [Abstract] |
BALANCE SHEET COMPONENTS | BALANCE SHEET COMPONENTS Inventory, net Our inventory, net, consisted of the following components (in thousands):
| March 31, 2023 |  | December 31, 2022
Purchased materials | $ | 25,475 |  |  | $ | 24,139 |
Work in process | 21,705 |  |  | 14,062 |
Finished goods | 14,775 |  |  | 12,180 |
Inventory, net | $ | 61,955 |  |  | $ | 50,381 |
Intangible Assets and Goodwill Intangible assets include acquired in-process research and development ("IPR&D") of $400 million as a result of the Omniome acquisition in September 2021. The IPR&D will remain on our Consolidated Balance Sheet as an indefinite-lived intangible asset until the completion or abandonment of the associated research and development activities. During the development period following the acquisition, IPR&D will not be amortized, but instead will be tested for impairment annually and more frequently if events or changes in circumstances indicate that it is more likely than not that the asset is impaired. Upon completion of the development, we will begin to amortize the asset over the life of the product, or record an impairment charge if the asset is determined to be impaired. In addition to IPR&D, definite-lived intangible assets included the following (in thousands, except years):
|  |  | As of March 31, 2023 |  | As of December 31, 2022
| Estimated Useful Life (in years) |  | Gross Carrying Amount |  | Accumulated Amortization |  | Net Carrying Amount |  | Gross Carrying Amount |  | Accumulated Amortization |  | Net Carrying Amount
Developed technology | 15 |  | $ | 11,179 |  |  | $ | (1,228) |  |  | $ | 9,951 |  |  | $ | 11,179 |  |  | $ | (1,039) |  |  | $ | 10,140 |
Customer relationships | 2 |  | 360 |  |  | (300) |  |  | 60 |  |  | 360 |  |  | (255) |  |  | 105 |
Total |  |  | $ | 11,539 |  |  | $ | (1,528) |  |  | $ | 10,011 |  |  | $ | 11,539 |  |  | $ | (1,294) |  |  | $ | 10,245 |
The estimated future amortization expense of intangible assets with definite lives is as follows (in thousands):
Remainder of 2023 | $ | 619 |
2024 | 745 |
2025 | 745 |
2026 | 745 |
2027 | 746 |
2028 and thereafter | 6,411 |
Total | $ | 10,011 |
We review definite-lived intangible assets for impairment when indication of potential impairment exists, such as a significant reduction in cash flows associated with the assets. Goodwill is reviewed for impairment at least annually during the second quarter, or more frequently if an event occurs indicating the potential for impairment. We performed our annual assessment for goodwill impairment in the second quarter of 2022, noting no impairment. Deferred Revenue On June 24, 2022, we entered into an Amended and Restated Development and Commercialization Agreement (the “Amended and Restated Agreement”) with Invitae Corporation (“Invitae”). During the three months ended March 31, 2023, Invitae did not purchase any of the instruments or consumables under the terms of the Amended and Restated Agreement. As of March 31, 2023 and December 31, 2022, $21.4 million of deferred revenue, current, is recorded on the Condensed Consolidated Balance Sheet relating to all future performance obligations under the Amended and Restated Agreement. Refer to Note 3 – Invitae Collaboration, in Part II, Item 8 of the Annual Report on Form 10-K for the year ended December 31, 2022 for more information. As of March 31, 2023, we had a total of $32.7 million of deferred revenue, $30.9 million of which was recorded as deferred revenue, current, and primarily relates to future performance obligations under the Amended and Restated Agreement with Invitae. The deferred revenue, non-current balance of $1.8 million primarily relates to deferred service contract revenues and is scheduled to be recognized in the next 5 years. Revenue recorded in the three months ended March 31, 2023 includes $3.5 million of previously deferred revenue that was included in deferred revenue as of December 31, 2022. Product Warranties We generally provide a one-year warranty on instruments. In addition, we provide a limited warranty on consumables. At the time revenue is recognized, an accrual is established for estimated warranty costs based on historical experience as well as anticipated product performance. We periodically review the warranty reserve for adequacy and adjust the warranty accrual, if necessary, based on actual experience and estimated costs to be incurred. Warranty expense is recorded as a component of cost of product revenue. There were no material changes in estimates for the periods presented below. Changes in the reserve for product warranties were as follows for the periods indicated (in thousands):
| Three Months Ended March 31, |  |
| 2023 |  | 2022 |  |  |  |
Balance at beginning of period | $ | 1,651 |  |  | $ | 594 |  |  |  |  |
Additions charged to cost of product revenue | 604 |  |  | 953 |  |  |  |  |
Repairs and replacements | (631) |  |  | (373) |  |  |  |  |
Balance at end of period | $ | 1,624 |  |  | $ | 1,174 |  |  |  |  |
Term loans In connection with the acquisition of Omniome, we acquired $1.3 million in short-term debt and $3.0 million in long-term debt relating to a term loan facility that Omniome obtained in April 2020. Borrowings on the term loan facility were used to fund Omniome’s purchases of equipment, which serves as collateral. Each term loan has a term of 43 months and bears a fixed interest rate of approximately 17% annually. The fee for the elective option to prepay all, but not less than all, of the borrowed amounts at any time after the 24 th month and before the 43 rd month after the commencement date, is 4% of the outstanding loan balance. Payments are made in equal monthly installments including principal and interest. As of March 31, 2023, the carrying value of term loans outstanding was $1.9 million. The related long-term portion of $0.2 million was recorded as part of other liabilities, non-current and the short-term portion of $1.7 million was recorded as part of other liabilities, current on the Condensed Consolidated Balance Sheet. The interest expense was $0.1 million for the three months ended March 31, 2023, which was included as part of interest expense in the Condensed Consolidated Statement of Operations and Comprehensive Loss. The following table presents the future principal payments on the term loans (in thousands):
Remainder of 2023 | $ | 1,395 |
2024 | 490 |
Total | $ | 1,885 |

X
- Definition Supplemental Balance Sheet Components Disclosure [Abstract] + References No definition available. + Details
Name: | pacb_SupplementalBalanceSheetComponentsDisclosureAbstract
Namespace Prefix: | pacb_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -URI https://asc.fasb.org/topic&trid=2122208 + Details
Name: | us-gaap_SupplementalBalanceSheetDisclosuresTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration